| Literature DB >> 33691518 |
Josephine Palandri1, Sharon L Smith2,3, David J Heal1,3, Sue Wonnacott4, Chris P Bailey1.
Abstract
BACKGROUND: α7 Nicotinic acetylcholine receptors are implicated in the reinstatement of drug-seeking, an important component of relapse. We showed previously that the α7 nicotinic acetylcholine receptor antagonist, methyllycaconitine, specifically attenuated morphine-primed reinstatement of conditioned place preference in rodents and this effect was mediated in the ventral hippocampus. AIMS: The purpose of this study was to evaluate α7 nicotinic acetylcholine receptor antagonism in reinstatement of the conditioned place preference for the more widely abused opioid, heroin, and to compare the effect of α7 nicotinic acetylcholine receptor blockade on reinstatement of heroin-seeking and heroin self-administration in an intravenous self-administration model of addictive behaviour.Entities:
Keywords: Heroin; abuse; conditioned place preference; drug-seeking; intravenous self-administration; opioid; reinstatement; relapse
Mesh:
Substances:
Year: 2021 PMID: 33691518 PMCID: PMC8521373 DOI: 10.1177/0269881121991570
Source DB: PubMed Journal: J Psychopharmacol ISSN: 0269-8811 Impact factor: 4.153
Figure 1.Effect of methyllycaconitine (MLA) on the stages of heroin conditioned place preference (CPP) in male Wistar rats. (a) Acquisition: rats were tested for innate preference (habituation), and then pseudo-randomly assigned to two groups with comparable mean preference scores. The MLA treatment group received MLA (◻, 4 mg/kg, s.c.) 20 min prior to a conditioning dose of heroin (1 mg/kg, s.c.), paired with the drug-paired compartment, and prior to saline, in the unpaired compartment, alternating over four consecutive days. The control group received saline (○, 1 mL/kg, s.c.) instead of MLA. A post-conditioning preference test was conducted the day after the last conditioning session (test day 9), in which rats had free access to the CPP apparatus compartments for 15 min. Preference scores indicate the time spent in the heroin-paired compartment in seconds minus 450 (half the total time). **p < 0.01, two-way analysis of variance (ANOVA) with Bonferroni post-hoc test, n = 12 per treatment group. (b) Expression: 12 rats (◊, ○, □) were conditioned to acquire heroin CPP as in (a) and were tested for preference for the drug paired side (test day 9). Rats marked ◊ were sacrificed prior to further testing. Rats marked ○ and □ in the habituation and test day 9 were subsequently administered either saline (•) or MLA (■) in the expression test (test day 12). Three days after the post conditioning test, rats were pseudo-randomly assigned to a treatment group and given either saline (•) or MLA (◻, 4 mg/kg, s.c.) 20 min prior to an additional 15-minute preference test (test day 12). *p < 0.05, habituation vs test day 9, n = 12 (paired t-test); n = 4 per treatment group for expression (test day 12; paired t-test). (c) Reinstatement: left: rats were tested for initial preference (◊, habituation), then conditioned to acquire heroin CPP as in (a), followed by 9 days of extinction (saline injections only, paired with alternate compartments on different days). All rats acquired heroin CPP (♦, test day 9) and showed no significant preference in the post-extinction test (∆, test day 23, *p < 0.05, two-way ANOVA with Bonferroni post-hoc analysis vs habituation, n = 37). Right: on the reinstatement test day 26, rats were assigned to one of four treatment groups with comparable mean preference scores from habituation (◊), post-conditioning (♦, test day 9) and post-extinction (∆, test day 23): saline control (○, Saline+Saline, n = 10), heroin reinstatement (•, Saline+Heroin, n = 8), MLA control (□, MLA+Saline, n = 9) or MLA reinstatement (◻, MLA+Heroin, n = 10), where MLA (4 mg/kg, s.c.) or saline was administered 20 min prior to a priming dose of heroin (1 mg/kg, s.c.) or saline (1 mL/kg, s.c.). Rats were then placed free-roaming in an extended preference test (30 min); data from the second 15 min bin are presented. ***p < 0.005, two-way ANOVA with Bonferroni post-hoc analysis vs heroin reinstatement. Data are expressed as mean ± standard error of the mean (SEM).
Figure 2.Effect of methyllycaconitine (MLA) on different phases of heroin intravenous self-administration (IVSA). (a) Effect of MLA on active lever responding behaviour (time to first press and presses per minute) for a food reward (fixed ratio (FR)3). (b) Effect of MLA on the heroin- and cue-primed reinstatement of drug-seeking behaviour. Following extinction, rats were pseudo-randomly assigned to two treatment groups and were administered saline (○, 1 mL/kg, s.c. n = 7) or MLA (◻, 4 mg/kg, s.c. n = 8) 20 min prior to a reinstatement test session, initiated by administration of a priming heroin dose (15 µg/kg, intravenous (i.v.)) and non-contingent presentation of the tone and light cues. Rats received saline infusions paired with the tone and light cues upon the correct number of active lever-presses (FR5). **p = 0.002, ***p < 0.001, multiple t-test. (c) Effect of MLA on the reinstatement of heroin IVSA. Rats were administered saline (○, 1 mL/kg, s.c. n = 7) or MLA (◻, 4 mg/kg, s.c. n = 8) 20 min prior to a reinstatement test session, initiated by a non-contingent heroin infusion (15 µg/kg, i.v.) paired with the tone and light cues. The correct number of active lever-presses (FR5) resulted in heroin injections (15 µg/kg/inj) paired with the tone and light cues. ***p < 0.001, multiple t-test. (d) The effect of MLA on the relative reinforcing efficacy of heroin was examined by breakpoint analysis in a single progressive ratio session. After reinstatement as in (c), rats (n = 15) remained in their treatment groups and were administered saline (○, 1 mL/kg, s.c.) or MLA (◻, 4 mg/kg, s.c.) 20 min prior to a single progressive ratio session. The session was initiated by a non-contingent injection of heroin (15 µg/kg, i.v.) paired with the tone and light cues. The number of active lever-presses, which resulted in a heroin injection (15 µg/kg/inj) paired with the tone and light cues, was logarithmically increased. Number of lever-presses per infusion (left panel) and number of infusions received (right panel) were recorded.
Progressive ratio schedule.
| No of lever-presses | 5 | 7 | 9 | 12 | 15 | 20 | 25 | 32 | 40 | 50 | 62 | 77 | 95 | 118 | 145 | 178 | 219 | 268 | 328 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative rewards | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
Animal models commonly used to investigate aspects of drug reward, reinforcement (abuse) and dependence.
| Aspect of drug reward/reinforcement/dependence | Animal model |
|---|---|
|
| |
| Reward + contextual association | CPP |
| Passive development of ‘drug-liking’ | |
|
| |
| Reward + contextual association | IVSA meeting the following criteria: |
| Escalating volitional drug intake | (a) The animals have satisfied the criteria for robust and prolonged drug self-administration (acquisition) |
| Drug craving | (b) The animals have undergone extinction to eliminate false responders |
|
| |
| Escalating volitional drug intake | IVSA in animals that have either been allowed to self-administer drugs without limits for prolonged periods (e.g. 24 h access for a period of weeks), or IVSA experiments performed in animals that have been rendered physically dependent by administering large doses of drugs to them for prolonged periods. |
| Drug craving | |
| Pharmacological tolerance | |
| Physical dependence on withdrawal | |
CPP: conditioned place preference; IVSA: intravenous self-administration.
Drug reward: the psychoactive properties of the substance produce pleasurable experiences that can lead to voluntary escalation of intake and the development of psychological dependence (reinforcement) leading to drug-seeking (craving).
Abuse (psychological dependence): state in which craving for the rewarding effect of the substance produces compulsive and perseverative drug-seeking and taking (reinforcement). In psychological dependence, the balance of motivation is still in favour of the positive effects (reward) over the negative effects (preventing the negative psychological consequences of abstinence (craving)).
Dependence (psychological and physical): escalating substance intake driven by the development of pharmacological tolerance, and in the case of the opiates, physical dependence during periods of withdrawal/abstinence. In substance dependence, the balance of motivation for abuse shifts from positive effects (reward) to negative effects (to prevent the negative consequences of abstinence of psychological dependence (craving) and physical dependence (withdrawal)).
Figure 3.Cascade for the development of opiate liking, psychological dependence, reinstatement of drug-seeking and relapse to opiate abuse showing the aspects where the involvement of α7 nicotinic receptor systems have been investigated. CPP: conditioned place preference; MLA: methyllycaconitine; nAChR: nicotinic acetylcholine receptor.
Source: results taken from: Wright et al. (2019),1 this study,2 Feng et al. (2011).3